Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR-SR vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and antagonizing adenosine receptors.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and prevention of asthma,Treatment of chronic bronchitis and emphysema (COPD),Apnea of prematurity (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/m L).
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Extensive first-pass metabolism. Metabolites excreted renally.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40% bound, primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.45 L/kg. Distributes into total body water; higher in premature infants and patients with cirrhosis.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral (extended-release): 96-100%.
Oral: 40-50%; Inhalation: 20-30%
No specific GFR-based dose adjustment required; use with caution in renal impairment due to altered clearance; monitor serum concentrations.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B: Reduce dose by 50% and monitor closely. Child-Pugh Class C: Consider alternative therapy; if used, reduce dose by 75% with frequent monitoring.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Children >1 year: Initial 16 mg/kg/day or 400 mg/day (whichever is less) divided every 12 hours; maximum dose: 24 mg/kg/day (not to exceed 900 mg/day). Target serum concentration 5-15 mcg/m L.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Over 60 years: Lower initial dose (e.g., 300 mg/day) due to decreased clearance; titrate slowly; monitor serum theophylline concentrations closely to avoid toxicity.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Dose-related adverse effects include seizures and arrhythmias.
No FDA black box warning.
Risk of seizure and arrhythmia at toxic levels; monitor serum theophylline concentrations closely. Use with caution in patients with heart failure, hepatic impairment, chronic alcoholism, and viral infections. Interactions with drugs affecting CYP1A2 (e.g., ciprofloxacin, fluvoxamine, smoking cessation) require dose adjustment.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation. Patients with pre-existing cardiac arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) unless controlled. History of seizure disorder (use only if benefits outweigh risks).
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
High-fat meals may increase absorption; avoid drastic dietary changes. Concurrent caffeine intake can increase theophylline effects and toxicity risk. Charcoal-broiled foods and a high-protein diet may decrease theophylline levels. Grapefruit juice may increase theophylline levels (moderate interaction).
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline crosses the placenta. First trimester: No clear evidence of major malformations in human studies, but animal studies show some risk at high doses (skeletal variations). Second trimester: No specific risks; use if benefit outweighs risk. Third trimester: Fetal tachycardia, jitteriness, and withdrawal symptoms (irritability, vomiting) in neonates due to transplacental accumulation. Avoid near term if possible.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk. Milk/plasma ratio approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose, leading to potentially therapeutic or toxic levels in infant serum. Possible effects include irritability, insomnia, and feeding intolerance. Use with caution; monitor infant for adverse effects.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Significant pharmacokinetic changes: increased clearance due to hepatic induction and increased renal excretion; decreased protein binding. May require dose increase. Monitor serum concentrations frequently (every 2-4 weeks) and adjust to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance decreases; reduce dose to prevent toxicity.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theolair-SR is a sustained-release theophylline formulation. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L) to avoid toxicity, especially in patients with hepatic impairment or those on interacting drugs. Tachyphylaxis may occur with chronic use. Caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias. Levels may be affected by smoking cessation, fever, or medications like cimetidine, fluoroquinolones, and macrolides.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take this medication exactly as prescribed; do not crush or chew the sustained-release tablets.,Avoid taking with large amounts of caffeine (coffee, tea, soda) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, restlessness, insomnia, rapid heartbeat, or seizures.,Do not change brands or dosing schedule without consulting your provider.,Maintain consistent intake of food and avoid sudden changes in diet that may affect absorption.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR-SR vs AEROLATE III, answered by our medical review team.
THEOLAIR-SR is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and antagonizing adenosine receptors.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR-SR and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR-SR is: Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/m L).. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR-SR and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR-SR is classified as Category C. Theophylline crosses the placenta. First trimester: No clear evidence of major malformations in human studies, but animal studies show some risk at high doses (skeletal variations). AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.